# Crescent Biopharma

Source: https://onco.cc/companies/crescent-biopharma/  
OnCo record `crescent-biopharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Crescent Biopharma is developing an antibody that blocks two cancer pathways at once, the PD-1 immune brake and the VEGF blood-vessel signal, alongside antibody-drug conjugates. Its lead antibody is in an international phase 1/2 trial.

## Summary

Crescent Biopharma was incorporated in Delaware on 19 September 2024 to develop antibody and ADC candidates licensed from Paragon Therapeutics, and became a Nasdaq-listed company (CBIO) through a reverse recapitalisation with GlycoMimetics on 16 June 2025. Its lead CR-001 is a PD-1 x VEGF bispecific antibody enrolling in the global phase 1/2 ASCEND trial, including cohorts combined with standard chemotherapy. CR-002 is a PD-L1-directed ADC with a topoisomerase inhibitor payload, whose IND the FDA cleared in October 2026, and CR-003 is SKB105, an ITGB6-directed ADC licensed from Sichuan Kelun-Biotech for territories outside Greater China.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: Crescent Biopharma, Inc.
- HQ: Waltham, MA
- Type: biotech
- Website: https://www.crescentbiopharma.com/
- Ticker: CBIO

## Notes

- Founding date, merger date and licence origins are from the company's 10-K for 2025 filed with the SEC (CIK 0001253689); ticker and exchange from SEC EDGAR submissions data. The concurrent private placement amount at the merger was not read in a primary source and is omitted. ITGB6 has no target record and is not linked. The investor relations site refused automated reading, so October 2026 pipeline items come from the company homepage.

## Sources

- Official website: https://www.crescentbiopharma.com/
- Form 10-K for 2025 (SEC): https://www.sec.gov/Archives/edgar/data/1253689/000162828026011983/cbio-20251231.htm
- CR-002 IND clearance, October 2026: https://investors.crescentbiopharma.com/news-releases/news-release-details/crescent-biopharma-announces-fda-clearance-ind-application-cr

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- targets: [PD-1](https://onco.cc/targets/pd1/), [PD-L1](https://onco.cc/targets/pdl1/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- trials: [CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct07335497/)

---
JSON: https://onco.cc/api/v1/entities/crescent-biopharma.json